Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07513116
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • intermittent fasting — OTHER
    They will fast for 16 consecutive hours each day and have an 8-hour window for eating.

Study Details

To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic, inflammatory, microbiome, and imaging-related markers.

Key Dates

Start date
Sep 17, 2026
Status verified
Apr 2026
Primary completion
Mar 30, 2027
Completion
Mar 30, 2029

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Intermittent fasting
    Fast for 16 consecutive hours each day and have an 8-hour window for eating.

Primary Outcome Measure

Safety and adverse events (AEs). [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Florencia McAllister, MD
[email protected]
713-745-0914
Florencia McAllister, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
MD Anderson Cancer Center· Houston, TX

Related Studies